{"id":58320,"date":"2026-04-30T16:24:09","date_gmt":"2026-04-30T16:24:09","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/58320\/"},"modified":"2026-04-30T16:24:09","modified_gmt":"2026-04-30T16:24:09","slug":"novartis-alector-merck-alnylm-uniqure-readout-newsletter","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/58320\/","title":{"rendered":"Novartis, Alector, Merck, Alnylm, UniQure : Readout Newsletter"},"content":{"rendered":"<p>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\" rel=\"nofollow noopener\" target=\"_blank\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/p>\n<p>Move over, GLP-1s. A preclinical next-gen obesity drug is stacking five mechanisms (in mice). Also, the NIH funding climate is rougher than ever, Novartis is reshoring more of its manufacturing,\u00a0and another Alzheimer\u2019s program is scuttled.<\/p>\n<p>The need-to-know this morning<\/p>\n<p>It\u2019s far harder to get an NIH grant these days<\/p>\n<p>The odds of landing an NIH grant have cratered to near-unsustainable levels. Only 13% of applications were funded last year, STAT\u2019s Anil Oza writes, with even top-scoring proposals no longer having good odds. Now, researchers are scrambling to survive in a system that\u2019s become both hypercompetitive and opaque.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter&hellip;\n","protected":false},"author":2,"featured_media":58321,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[336,324,1000,206,338],"class_list":{"0":"post-58320","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-biotechnology","9":"tag-drug-development","10":"tag-drug-prices","11":"tag-novartis","12":"tag-research"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116494589350200245","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/58320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=58320"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/58320\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/58321"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=58320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=58320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=58320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}